PRKN and osteoporosis: Furthermore, octyl itaconate inhibits inflammation and osteoclastogenesis by inhibiting the E3 ubiquitin ligase Hrd1 and activating Nrf2 signaling, demonstrating potential application value in the treatment and prevention of osteoporosis (Sun et al., 2019).